HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Liver transplantation for solitary hepatocellular carcinoma less than 3 cm in diameter in Child A cirrhosis.

Abstract
Liver transplantation for hepatocellular carcinoma (HCC) is the treatment of choice for patients with unresectable tumors within the Milan criteria associated with Child B or C cirrhosis. Liver transplantation provides the best cure for both the HCC and the underlying cirrhosis. In recent years, some authors have advocated liver transplantation even for resectable early HCC associated with Child A cirrhosis, leading to a controversy of whether resection or transplantation should be the first-line therapy for patients with small HCC in Child A cirrhosis. Recent studies comparing liver resection and transplantation for early HCC demonstrated similar long-term survival of 60-70%, but liver transplantation is associated with a lower tumor recurrence rate. However, the current shortage of deceased donor liver grafts limits the applicability of liver transplantation for HCC. The use of live donor liver transplantation for patients with a small solitary HCC in Child A cirrhosis that is resectable may not be justified ethically because of the potential risk to the donors. Patients put on a transplantation waiting list run a significant risk of tumor progression and dropout, while liver resection is immediately applicable to all. Advocating primary liver transplantation for patients with early HCC associated with compensated cirrhosis will increase the waiting time for transplantation and further increases the chance of dropout. Resection first and salvage transplantation for recurrent tumors or liver failure is an alternative strategy that may reduce the use of liver grafts. However, the long-term survival result of such a strategy compared with primary liver transplantation remains unclear.
AuthorsRonnie T P Poon
JournalDigestive diseases (Basel, Switzerland) (Dig Dis) Vol. 25 Issue 4 Pg. 334-40 ( 2007) ISSN: 1421-9875 [Electronic] Switzerland
PMID17960069 (Publication Type: Journal Article)
Copyright(c) 2007 S. Karger AG, Basel.
Topics
  • Carcinoma, Hepatocellular (mortality, pathology, surgery)
  • Catheter Ablation
  • Combined Modality Therapy
  • Hepatectomy
  • Humans
  • Liver Cirrhosis (complications, pathology)
  • Liver Neoplasms (mortality, pathology, surgery)
  • Liver Transplantation
  • Neoplasm Recurrence, Local (surgery)
  • Patient Dropouts
  • Patient Selection
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: